Compare AbCellera Biologics Inc (ABCL) vs Boston Scientific Corporation (BSX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Boston Scientific Corporation — how do they compare? AbCellera Biologics Inc trades at $7.15 (market cap $2.35B), while Boston Scientific Corporation trades at $44.68 (market cap $67.33B). The key difference: Boston Scientific Corporation is far larger — about 28.7× AbCellera Biologics Inc's market cap, and AbCellera Biologics Inc is trading nearer its 52-week high, Boston Scientific Corporation nearer its low. Which is the better fit depends on your goals.
| ABCL | BSX | |
|---|---|---|
Market Cap | $2.35B | $67.33B |
Sector | Health | Health |
52-Week High | $8.12 | $108.14 |
52-Week Low | $2.78 | $42.68 |
Enterprise Value | $1.99B | $76.91B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Boston Scientific (BSX) trades at $45.30, showing modest daily gains of 0.35% amid a bearish technical trend. The company demonstrates strong fundamentals with consistent earnings beats, revenue growth from $12.7B in 2022 to $20.1B in 2025, and robust profitability margins. Recent news highlights a significant price decline from all-time highs, creating valuation opportunities despite competitive pressures in key segments like electrophysiology.
The investment outlook remains positive based on strong analyst consensus (88% buy ratings) and a $73.63 price target implying 63% upside. Key risks include growth deceleration in core products and market volatility. Fundamentals support long-term value, but investors should monitor execution against revised guidance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →
